In-line with XVIVO’s dedication to the US market, Fredrik Dalborg is appointed MD North America

To successfully execute on XVIVO’s strategy, Fredrik Dalborg has been appointed Managing Director North America and will become a member of the XVIVO executive management team. North America is XVIVO’s most important region where XVIVO anticipate strong growth over the next few years, and also to become market leader in all major organs. Fredrik will lead the full North America commercial team and be responsible for the overall US operations.

Fredrik Dalborg has considerable international medical technology experience after having worked more than 10 years for Terumo BCT – a US based global leader in blood component and cellular technologies.

In addition, he has served as CEO and Group President at ETAC AB – a world leading developer of ergonomic mobility aids and patient handling equipment – and Boule Diagnostics – a global diagnostics company that develops, manufactures, and markets instruments and consumable products for blood diagnostics.

Fredrik holds a Master of Science in Economics and Business Administration from Stockholm School of Economics, Sweden, and has also served 4 years in the Royal Swedish Navy.

Based in Philadelphia, the US, he will commence his role December 15, 2021.

“The US is the world’s largest transplant market and will keep that position for the coming years. Today we are market leaders in lungs and have the strategy in place for all major organs. I am certain that we will continue our successful journey in the US with Fredrik in a leadership role. He is a well-rounded business leader with a global mindset resulting from his exposure to multinational companies and a strong drive for results. I wish him all success in this exciting role” says Dag Andersson CEO XVIVO. Accesswire